Evidence map›Paper›PMID 38163420›Full record

ArticleRedox biology2024

Bile duct ligation elevates 5-HT levels in cerebral cortex of rats partly due to impairment of brain UGT1A6 expression and activity via ammonia accumulation.

Hanyu Yang, Linjun You, Zhongyan Wang, Lu Yang, Xun Wang, Wenhan Wu, Hao Zhi, Guangmei Rong, Yun Sheng, Xiaodong Liu and 1 more

Open access · goldAbstract read
In one paragraph

Article in Redox biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
3.7field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. UGT1A6 in pancreatic cancer: a promising prognostic biomarker and therapeutic target.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025
    Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Hanyu YangState Key Laboratory of Natural Medicines, Key Laboratory of Drug Metabolism and Pharmacokinetics, China Pharmaceutical University, 210009, Nanjing, China; Department of Pharmacology, School of Pharmacy, China Pharmaceutical University, Nanjing, 210009, China.
Linjun YouCenter for New Drug Safety Evaluation and Research, China Pharmaceutical University, 210009, Nanjing, China.
Zhongyan WangDepartment of Pharmacology, School of Pharmacy, China Pharmaceutical University, Nanjing, 210009, China.
Lu YangDepartment of Pharmacology, School of Pharmacy, China Pharmaceutical University, Nanjing, 210009, China.
Xun WangDepartment of Pharmacology, School of Pharmacy, China Pharmaceutical University, Nanjing, 210009, China.
Wenhan WuDepartment of Pharmacology, School of Pharmacy, China Pharmaceutical University, Nanjing, 210009, China.
Hao ZhiDepartment of Pharmacology, School of Pharmacy, China Pharmaceutical University, Nanjing, 210009, China.
Guangmei RongDepartment of Pharmacology, School of Pharmacy, China Pharmaceutical University, Nanjing, 210009, China.
Yun ShengDepartment of Pharmacology, School of Pharmacy, China Pharmaceutical University, Nanjing, 210009, China.
Xiaodong LiuState Key Laboratory of Natural Medicines, Key Laboratory of Drug Metabolism and Pharmacokinetics, China Pharmaceutical University, 210009, Nanjing, China; Department of Pharmacology, School of Pharmacy, China Pharmaceutical University, Nanjing, 210009, China. Electronic address: xdliu@cpu.edu.cn.
Li LiuState Key Laboratory of Natural Medicines, Key Laboratory of Drug Metabolism and Pharmacokinetics, China Pharmaceutical University, 210009, Nanjing, China; Department of Pharmacology, School of Pharmacy, China Pharmaceutical University, Nanjing, 210009, China. Electronic address: liulee@cpu.edu.cn.
China Pharmaceutical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatic encephalopathy (HE) is often associated with endogenous serotonin (5-HT) disorders. However, the reason for elevated brain 5-HT levels due to liver failure remains unclear. This study aimed to investigate the mechanism by which liver failure increases brain 5-HT levels and the role in behavioral abnormalities in HE. Using bile duct ligation (BDL) rats as a HE model, we verified the elevated 5-HT levels in the cortex but not in the hippocampus and striatum, and found that this cortical 5-HT overload may be caused by BDL-mediated inhibition of UDP-glucuronosyltransferase 1A6 (UGT1A6) expression and activity in the cortex. The intraventricular injection of the UGT1A6 inhibitor diclofenac into rats demonstrated that the inhibition of brain UGT1A6 activity significantly increased cerebral 5-HT levels and induced HE-like behaviors. Co-immunofluorescence experiments demonstrated that UGT1A6 is primarily expressed in astrocytes. In vitro studies confirmed that NH

Indexed as

Liver FailureSerotoninAmmoniaAnimalsBile DuctsBrainCerebral CortexGlucuronosyltransferaseRatsReactive Oxygen SpeciesAmmoniaGlucuronosyltransferaseReactive Oxygen SpeciesSerotoninUDP-glucuronosyltransferase, UGT1A7AmmoniaHepatic encephalopathyHepatocyte nuclear factor 4αReactive oxygen speciesSerotoninUDP-Glucuronosyltransferase 1A6

Identifiers

PMID38163420
PMCPMC10794929
OpenAlexW4390331655

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.